Latest / Stock Movers / 3M Profit Outlook Light; Netflix Amends Warner Bros. Deal; GSK to Buy Rapt Therapeutics
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg Data.
- 0:16Speaker 2: Right now are stock movers and there are stocks earnings
- 0:19Speaker 2: out forgot all about it. Three M the Minnesota mining
- 0:23Speaker 2: and manufacturing company, among others. Lisa Matteo a podcast.
- 0:28Speaker 3: Yes, let's start there. Okay, So ticker MMM. Their shares
- 0:31Speaker 3: have been down as much as five percent. So the
- 0:34Speaker 3: reason for it is it's profit forecast miss estimates, so
- 0:36Speaker 3: its shares are taking a hit despite the company gaining
- 0:39Speaker 3: more than twenty percent in the last twelve months. They've
- 0:42Speaker 3: been trying to revamp operations right, They've been reviving their
- 0:45Speaker 3: pipeline of new products, increasing efficiencies across its industrial base.
- 0:50Speaker 3: For example, if you look at it, you know they're
- 0:52Speaker 3: known for posted notes and things like that. Roofing ground
- 0:54Speaker 3: you as electronic materials, but it's electrical business. It's been
- 0:57Speaker 3: targeting clients in the data center space because of AI.
- 1:01Speaker 3: And then they have nuclear facilities that are being positioned
- 1:03Speaker 3: to help build new reactors because we've been hearing about
- 1:06Speaker 3: power demand on the rise. Those actually helped three M
- 1:10Speaker 3: in twenty twenty five. But the outlook shows that that
- 1:13Speaker 3: momentum is slowing, and so that's why it shares are
- 1:16Speaker 3: taking a hit this morning. The next one, Paul up
- 1:19Speaker 3: your alley, Netflix, NFLX. Their shares up more than one percent,
- 1:23Speaker 3: it reports after the close. But it's the news that
- 1:25Speaker 3: we've been talking about. It reached an amended all cash
- 1:28Speaker 3: agreement all cash, that's what they want to do with
- 1:30Speaker 3: the change the Warner Brothers Discovery streaming business offer. So
- 1:34Speaker 3: they're hoping it's going to speed up the sale. I'm guessing,
- 1:37Speaker 3: you know, thirty dollars a share cash tender is what
- 1:39Speaker 3: paramount offered for all of Warner They hope to call
- 1:42Speaker 3: a special meeting with shareholders to approve the deal. If
- 1:45Speaker 3: you look at a timeline Netflix, they say stockholders should
- 1:48Speaker 3: be able to vote on the transaction by April. But
- 1:51Speaker 3: I'm sure this all will take.
- 1:53Speaker 1: A lot more.
- 1:54Speaker 4: Fine, we'll see what paramounts you know, comes back with her.
- 1:57Speaker 4: Are they going to up their offer? That's probably the next.
- 1:59Speaker 2: Winning the battle right now. I mean, you know all
- 2:02Speaker 2: weekend land Man land Man, Landman, Yeah, oh did you watch.
- 2:07Speaker 4: I'm watching it on the train ride home today. So
- 2:09Speaker 4: I've DoD so no spoilers, No spoilers.
- 2:12Speaker 2: I got rave reviews about how they handled it good.
- 2:15Speaker 4: Yeah, because the second season, quite frankly, it's not been
- 2:17Speaker 4: as good.
- 2:18Speaker 2: As Does that save the small like your show like that?
- 2:21Speaker 2: Does it save them?
- 2:23Speaker 4: No, it's just one of many. Netflix has got a
- 2:25Speaker 4: huge portfolio of programming. But it's nice to get the
- 2:27Speaker 4: being ageist and that's what matters.
- 2:29Speaker 1: Sure, no spoilers exactly.
- 2:33Speaker 3: Next one of these, the last one, the San Francisco
- 2:36Speaker 3: based a biotech company is called Wrap Therapeutics. Shares are
- 2:39Speaker 3: up as much as sixty five percent, So basically we
- 2:43Speaker 3: got some deal making news. UK drug company GSK. They're
- 2:45Speaker 3: going to buy it in a deal valued at two
- 2:47Speaker 3: point two billion. What is RAP do? They develop treatments
- 2:51Speaker 3: for patients with inflammatory immune logic diseases. So GSK says
- 2:56Speaker 3: the deal is going to give it these global rights
- 2:57Speaker 3: to potential protection against food. Allur jins could require less
- 3:01Speaker 3: dosing than current standard, but they're now focused. GAGSK is
- 3:06Speaker 3: changing their focus. They want to double down on two
- 3:08Speaker 3: key parts in the business. Apps on collegy medicines and
- 3:10Speaker 3: also immunology inflammatory drugs. So some felmaking.
- 3:13Speaker 1: News, the Stock Mover's Report from Bloomberg Radio. Check back
- 3:19Speaker 1: with us throughout the day for the latest roundup of
- 3:21Speaker 1: companies making news on Wall Street and for the latest
- 3:24Speaker 1: market moving headlines. Listen to Bloomberg Radio Live, catch us
- 3:29Speaker 1: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 3:32Speaker 1: Auto with the Bloomberg Business app.